Linked Life Data

21584812

Source:http://linkedlifedata.com/resource/pubmed/id/21584812

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2011-6-24
pubmed:abstractText
Many hematological malignancies consist of tumor cells that are spontaneously recognized and killed by V?9V?2 T cells. These tumor cells generate high amounts of intracellular phosphorylated metabolites mimicking the natural ligands and display a wide range of stress-induced self-ligands that are recognized by V?9V?2 T cells via TCR-dependent and TCR-independent mechanisms. The intrinsic features of V?9V?2 T cells and that of tumor cells of hematological origin constitute an ideal combination from which to develop V?9V?2 T cell-based immune interventions. In this review, we will discuss the rationale, preclinical and clinical data in favor of this therapeutic strategy and the future perspectives of its development.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1420-9071
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2419-32
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
V?9V?2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
pubmed:affiliation
Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), and Divisione Universitaria di Ematologia, Ospedale San Giovanni Battista di Torino e Universita' degli Studi di Torino, Turin, Italy.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't